IN2014DN06118A - - Google Patents
Info
- Publication number
- IN2014DN06118A IN2014DN06118A IN6118DEN2014A IN2014DN06118A IN 2014DN06118 A IN2014DN06118 A IN 2014DN06118A IN 6118DEN2014 A IN6118DEN2014 A IN 6118DEN2014A IN 2014DN06118 A IN2014DN06118 A IN 2014DN06118A
- Authority
- IN
- India
- Prior art keywords
- oncogenic viral
- immune response
- polypeptide
- polypeptides
- subject
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 231100000590 oncogenic Toxicity 0.000 abstract 5
- 230000002246 oncogenic effect Effects 0.000 abstract 5
- 230000003612 virological effect Effects 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 230000000890 antigenic effect Effects 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261590089P | 2012-01-24 | 2012-01-24 | |
PCT/US2013/022696 WO2013112549A1 (en) | 2012-01-24 | 2013-01-23 | Polynucleotides for treating oncogenic viral polypeptide positive tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN06118A true IN2014DN06118A (de) | 2015-08-14 |
Family
ID=48873849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN6118DEN2014 IN2014DN06118A (de) | 2012-01-24 | 2013-01-23 |
Country Status (10)
Country | Link |
---|---|
US (3) | US9492526B2 (de) |
EP (2) | EP3269387B1 (de) |
JP (2) | JP6219849B2 (de) |
KR (1) | KR102195196B1 (de) |
CN (2) | CN104159607A (de) |
DK (1) | DK2806889T3 (de) |
ES (1) | ES2646590T3 (de) |
HK (1) | HK1203833A1 (de) |
IN (1) | IN2014DN06118A (de) |
WO (1) | WO2013112549A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6805139B2 (ja) | 2014-11-13 | 2020-12-23 | ウニヴァシテ デ ジュネーブUniversite De Geneve | ワクチンベクターとしての3分節型アレナウイルス |
US10669315B2 (en) | 2015-06-10 | 2020-06-02 | Hookipa Biotech Gmbh | HPV vaccines |
LT3371316T (lt) | 2015-11-04 | 2022-11-25 | Hookipa Biotech Gmbh | Vakcinos nuo hepatito b viruso |
JP7157662B2 (ja) | 2015-11-12 | 2022-10-20 | ホオキパ バイオテック ジーエムビーエイチ | 癌ワクチンとしてのアレナウイルス粒子 |
EP3400004A1 (de) | 2016-01-08 | 2018-11-14 | Vaccibody AS | Therapeutischer antikrebs-neoepitop-impfstoff |
GB201605210D0 (en) * | 2016-03-29 | 2016-05-11 | Oxford Immunotec Ltd | Assay |
US20190134195A1 (en) * | 2016-06-03 | 2019-05-09 | Etubics Corporation | Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases |
CN106655327A (zh) * | 2016-10-18 | 2017-05-10 | 云南中烟工业有限责任公司 | 一种压缩式充电装置 |
CN117370603A (zh) | 2016-11-11 | 2024-01-09 | 谷歌有限责任公司 | 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质 |
IL314393A (en) * | 2018-03-06 | 2024-09-01 | Precigen Inc | Human papillomavirus vaccines and their uses |
KR102712588B1 (ko) * | 2020-05-25 | 2024-10-02 | (주)진매트릭스 | 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도 |
CA3178325A1 (en) * | 2020-05-25 | 2021-12-02 | Soo Ok Kim | Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
WO1999061608A2 (en) * | 1998-05-26 | 1999-12-02 | Institute Of Molecular And Cell Biology | Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation |
JP4755422B2 (ja) * | 2002-10-03 | 2011-08-24 | ワイス・ホールディングズ・コーポレイション | ヒトパピローマウイルス・ポリペプチドおよび免疫原性組成物 |
AR065075A1 (es) * | 2007-05-15 | 2009-05-13 | Transgene Sa | Vectores para la expresion multiple de genes |
CA2760310A1 (en) | 2009-04-28 | 2010-11-11 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
CN102002105B (zh) * | 2009-09-03 | 2013-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途 |
-
2013
- 2013-01-23 KR KR1020147023589A patent/KR102195196B1/ko active IP Right Grant
- 2013-01-23 US US14/373,844 patent/US9492526B2/en active Active
- 2013-01-23 JP JP2014554791A patent/JP6219849B2/ja active Active
- 2013-01-23 EP EP17185609.9A patent/EP3269387B1/de active Active
- 2013-01-23 IN IN6118DEN2014 patent/IN2014DN06118A/en unknown
- 2013-01-23 DK DK13740950.4T patent/DK2806889T3/da active
- 2013-01-23 ES ES13740950.4T patent/ES2646590T3/es active Active
- 2013-01-23 CN CN201380012419.2A patent/CN104159607A/zh active Pending
- 2013-01-23 WO PCT/US2013/022696 patent/WO2013112549A1/en active Application Filing
- 2013-01-23 CN CN201910216555.2A patent/CN110042110A/zh active Pending
- 2013-01-23 EP EP13740950.4A patent/EP2806889B1/de active Active
-
2015
- 2015-05-12 HK HK15104469.7A patent/HK1203833A1/xx unknown
-
2016
- 2016-09-06 US US15/257,198 patent/US9969779B2/en active Active
-
2017
- 2017-09-28 JP JP2017188121A patent/JP6655051B2/ja active Active
-
2018
- 2018-04-11 US US15/950,819 patent/US20180237477A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9492526B2 (en) | 2016-11-15 |
JP6655051B2 (ja) | 2020-02-26 |
US20180237477A1 (en) | 2018-08-23 |
WO2013112549A1 (en) | 2013-08-01 |
ES2646590T3 (es) | 2017-12-14 |
US20160376324A1 (en) | 2016-12-29 |
JP6219849B2 (ja) | 2017-10-25 |
DK2806889T3 (da) | 2017-11-20 |
EP2806889A1 (de) | 2014-12-03 |
CN104159607A (zh) | 2014-11-19 |
EP3269387A1 (de) | 2018-01-17 |
US9969779B2 (en) | 2018-05-15 |
EP3269387B1 (de) | 2019-07-17 |
US20150023996A1 (en) | 2015-01-22 |
EP2806889A4 (de) | 2016-04-20 |
JP2015506179A (ja) | 2015-03-02 |
JP2018038405A (ja) | 2018-03-15 |
HK1203833A1 (en) | 2015-11-06 |
KR102195196B1 (ko) | 2020-12-28 |
KR20140131929A (ko) | 2014-11-14 |
CN110042110A (zh) | 2019-07-23 |
EP2806889B1 (de) | 2017-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN06118A (de) | ||
MX2020010035A (es) | Receptores de celulas t anti-papilomavirus 16 e7 humano. | |
MX2010007461A (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. | |
IN2014KN02929A (de) | ||
CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
IN2014DN10288A (de) | ||
MX363307B (es) | Plataformas para suministro de antigenos. | |
MX2015007575A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
WO2011103453A3 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
SG11201502189UA (en) | Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor | |
WO2010149752A3 (en) | Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease | |
NZ600974A (en) | Binding members for human cytomegalovirus | |
NZ627078A (en) | Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy | |
EA201692279A1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
MX2011007692A (es) | Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion. | |
IL220092A (en) | 44cd monoclonal antibody for use in the treatment of squamous cell carcinoma of the head and neck | |
UA112549C2 (uk) | Частинки на основі поліакрилату, що містять активну сполуку | |
EA201390617A1 (ru) | Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики | |
NZ594198A (en) | Neil3 peptides and vaccines including the same | |
EP3819306A3 (de) | E-glycoprotein-polypeptide des dengue-virus mit mutationen zur eliminierung von immundominanten kreuzreaktiven epitopen | |
SI2859092T1 (sl) | Terapevtsko cepivo za zdravljenje diabetesa tipa 1 pri otrocih, uporaba naprave za sortiranje celic in postopek multipliciranja TREG celic za pridobivanje terapevtskega cepiva za zdravljenje diabetesa tipa 1 | |
EP2940133A4 (de) | Impfstoff für hpv-infektion und/oder hepatitis b mit chimärem hpv/hbs-protein als wirkstoff | |
WO2012038832A3 (en) | Generation of replicating chimeric measles virus - retrovirus particles | |
WO2014060851A3 (en) | Hepatitis c virus immunogenic compositions and methods of use thereof |